论文部分内容阅读
背景:当前对女性接受经皮冠状动脉介入(PCI)后果的界定远不完善。REPLACE-2试验证实,就缺血和出血终点事件而言,在PCI时应用比伐卢定+临时糖蛋白IIb/IIIa(GpIIb-IIIa)阻断剂的后果并不劣于应用肝素+计划性GpIIb-IIIa阻断剂的后果。
Background: The current definition of the consequences of percutaneous coronary intervention (PCI) in women is far from perfect. The REPLACE-2 trial confirms that the consequences of PCI with bivalirudin + Temporary glycoprotein IIb / IIIa (GpIIb-IIIa) blockers are not inferior to those with heparin + schedules in terms of ischemic and bleeding endpoints Consequences of GpIIb-IIIa blockers.